Psilocybin Program

Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
Incannex Healthcare To Open First Psychedelic-Assisted Therapy Clinic In Australia
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
Incannex Healthcare To Open First Psychedelic-Assisted Therapy Clinic In Australia
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds

Psilocybin Program Recent News

Nasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business Combination
The duo comprised of clinical-stage natural psilocybin biotech Psyence Group Inc.
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD).
Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized Prescriber Scheme (
COMPASS Pathways Q3 2023 Results: Cash Injection To Sustain Phase 3 Psilocybin Program
COMPASS Pathways plc (NASDAQ: CMPS), the London-headquartered psychedelics biotech company reported financial results for the third quarter 2023 ended September 30, showing: 
Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find
Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003
EXCLUSIVE: Becoming Compliant In Today's Legal Psychedelics Markets With Allay Consulting
What can businesses and clients expect of the incoming psychedelic-assisted therapies (PAT) scenario? What are state regulations looking like from a for-profit perspective, and what does it take to provide safe, effective and regulations-compliant treatments?
Canada Approves Legal Medical Psilocybin Access For Veteran, To Undergo Apex's Macrodose Therapy (CORRECTED)
Editor's note: This story has been updated to clarify that Kelsi Sheren's treatment does not represent the first legal access to medical psilocybin in Canada. 
Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression
Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.) 
Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here
The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences (NASDAQ: ENVB). 
Congress To Discuss New Bill Banning Federal Intervention In States Where Psilocybin Is Legal
Democrat Reps. Robert Garcia and Earl Blumenauer filed a new bill in Congress that would discourage federal law enforcement and general intervention in states and localities that legalize or decriminalize psilocybin mushrooms.
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Psychedelics Reform Update: CA Bill's Final Vote, MA 2024 Legalization Ballot, HI Task Force, OR Funding And More
A number of states are moving reform bills concerning the study or straight out legalizing the use of psychedelic substances for therapeutic purposes. Others have already passed legislation and its implementation is underway.
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
COMPASS Pathways plc (NASDAQ: CMPS) shared the results from research on the potential of its novel AI technologies to support its proprietary COM
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, New Usona Phase 2 Trial Shows
Nonprofit medical research organization the Usona Institute shared the results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for 104 adults with Major Depressive Disorder (MDD,) providing further evidence of the psychedelic’s
Red Light Holland's Q1 2024 Performance: Revenue Soars 53% And Solid Cash Balance
Ontario-based mushrooms producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements, management discussion and analysis for the three months ended June 30. The Numbers:
From Ice Rink To Healing Haven: Former NHL Player Sets Up Psilocybin Therapy Center In Colorado
As professional athletes continue to endorse psychedelic-assisted therapy, former Colorado Avalanche defenseman Kyle Quincey is taking it to the next level.
Morgan Stanley And TD Cowen Lead Financing Of Up To $285M For Psychedelics Company: Private Placement Backed By 'Select Group' Of Investors
Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group of healthcare specialist investors. 
Filament Health Shares Q1 2023 Financials, Material Uncertainties Upon Securing Additional Financing
Natural psychedelic drug development company Filament Health (OTCQB: FLHLF) has released its unaudited consolidated, condensed financial results for Q1 2023 ended June 30. Numbers show:
Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
Novel psychedelic-based drugs biotech Mydecine Innovations Group (OTC: MYCOF) shared its financial results for the six months ended June 30, 2023. Second quarter of FY2023 looks like this: Cash position of $29.987 (CA $40,458) as of June 30, 2023.
COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady Quarter And 'Strong Progress Across The Business'
Psychedelics biotech COMPASS Pathways’ (NASDAQ: CMPS) consolidated unaudited financial results for the second quarter 2023, ended June 30 are as follows:
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances with that of classic drugs. 
Natural Psilocybin Companies Diversify: Latest By Optimi, Red Light Holland And A European Player
Optimi Completes Novel Extraction Process and Files U.S. Prov. Patent
Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
Rose Hill, a Jamaica-based cultivator, supplier and exporter of premium psilocybin products and biomass to research partners and brands is now offering its first wellness retreat program under the name ONE Retreats. 

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved